Business Wire

Gcore Unveils Inference at the Edge – Bringing AI Applications Closer to End Users for Seamless Real-Time Performance

6.6.2024 11:30:00 EEST | Business Wire | Press release

Share

Gcore, the global edge AI, cloud, network, and security solutions provider, today announced the launch of Gcore Inference at the Edge, a breakthrough solution that provides ultra-low latency experiences for AI applications. This innovative solution enables the distributed deployment of pre-trained machine learning (ML) models to edge inference nodes, ensuring seamless, real-time inference.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240606719181/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Gcore Inference at the Edge empowers businesses across diverse industries with cost-effective, scalable, and secure AI model deployment (Graphic: Gcore)

Gcore Inference at the Edge empowers businesses across diverse industries—including automotive, manufacturing, retail, and technology—with cost-effective, scalable, and secure AI model deployment. Use cases such as generative AI, object recognition, real-time behavioural analysis, virtual assistants, and production monitoring can now be rapidly realised on a global scale.

Gcore Inference at the Edge runs on Gcore's extensive global network of 180+ edge nodes, all interconnected by Gcore's sophisticated low-latency smart routing technology. Each high-performance node sits at the edge of the Gcore network, strategically placing servers close to end users. Inference at the Edge runs on NVIDIA L40S GPUs, the market-leading chip designed specifically for AI inference. When a user sends a request, an edge node determines the route to the nearest available inference region with the lowest latency, achieving a typical response time of under 30 ms.

The new solution supports a wide range of fundamental ML and custom models. Available open-source foundation models in the Gcore ML Model Hub include LLaMA Pro 8B, Mistral 7B, and Stable-Diffusion XL. Models can be selected and trained agnostically to suit any use case, before distributing them globally to Gcore Inference at the Edge nodes. This addresses a significant challenge faced by development teams where AI models are typically run on the same servers they were trained on, resulting in poor performance.

Benefits of Gcore Inference at the Edge include:

  • Cost-effective deployment: A flexible pricing structure ensures customers only pay for the resources they use.
  • Inbuilt DDoS protection: ML endpoints are automatically protected from DDoS attacks through Gcore’s infrastructure.
  • Outstanding data privacy and security: The solution features built-in compliance with GDPR, PCI DSS, and ISO/IEC 27001 standards.
  • Model autoscaling: Autoscaling is available to handle load spikes, so a model is always ready to support peak demand and unexpected surges.
  • Unlimited object storage: Scalable S3-compatible cloud storage that grows with evolving model needs.

Andre Reitenbach, CEO at Gcore comments: “Gcore Inference at the Edge empowers customers to focus on getting their machine learning models trained, rather than worrying about the costs, skills, and infrastructure required to deploy AI applications globally. At Gcore, we believe the edge is where the best performance and end-user experiences are achieved, and that is why we are continuously innovating to ensure every customer receives unparalleled scale and performance. Gcore Inference at the Edge delivers all the power with none of the headache, providing a modern, effective, and efficient AI inference experience.”

Learn more at https://gcore.com/inference-at-the-edge

About Gcore
Gcore is the global edge AI, cloud, network, and security solutions provider. Gcore provides its solutions to global leaders in numerous industries. The company manages its own global IT infrastructure across six continents, with one of the best network performances in Europe, Africa, and LATAM, due to the average response time of 30 ms worldwide. Gcore’s network consists of 180+ points of presence around the world in reliable Tier IV and Tier III data centres, with a total capacity exceeding 200 Tbps.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Gcore press contact
pr@gcore.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release

Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release

Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development

Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye